临床试验/IRCT20220211053992N14

IRCT20220211053992N14招募中Unknown

In vivo bioequivalence study of Pentoprazolr 40 mg capsule of Temad pharmaceutical Co. compared to innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2023年10月16日

适应症

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)
•Age (18-59 years old)

排除标准

•History of cardiovascular, liver and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence study of Pantoprazole 40mgHealthy volunteers.

IRCT20200623047902N7Sanamed pharma company24

Bioequivalence study of Pantoprazole 40 mg tabletThis study is performed on healthy volunteers..

IRCT20200623047902N33Ronak Pharm company24

Bio equivalence study of Esomeprazole 40 mgBio equivalence Esomeprazole 40 mg.

IRCT20200513047423N3Sina pishgam daru novin24

Bioequivalence study of manufactured by Esmoprazole 40mg Cap. Kooshan Pharmed. Co. (Eosoflux) in Iranian healthy volunteers

IRCT20200105046010N7Tabriz University of Medical Sciences24

Bioequivalence study of Phenazopyridine 100mg tabletThis study is performed on healthy volunteers..

IRCT20200623047902N31Ronak Pharm company24